CN Patent

CN118666832A — 作为smarca2/brm atp酶抑制剂的脲化合物和组合物

Assigned to Novartis AG · Expires 2024-09-20 · 2y expired

What this patent protects

提供了已表明可用于治疗BRM介导的和/或BRG1介导的疾病或障碍的具有式(I)的化合物或其药学上可接受的盐：式(I)，其中R 1 至R 6 如本文所定义。

USPTO Abstract

提供了已表明可用于治疗BRM介导的和/或BRG1介导的疾病或障碍的具有式(I)的化合物或其药学上可接受的盐：式(I)，其中R 1 至R 6 如本文所定义。

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: CN118666832A
Jurisdiction: CN
Classification: —
Expires: 2024-09-20
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.